PAC-14028 cream 1.0% or placebo will be treated to Mild to Moderate Atopic Dermatitis patients twice daily for 8 weeks.
This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.